Maria Alyce Albuquerque Fernandes1,2*†
Francisca Lidiane Linhares de Aguiar2†Maria Gleiciane Soares Coutinho2†Erika Helena Salles de Brito3†Camila Gomes Virginio Coelho4†Raquel Oliveira dos Santos Fontenelle2†- 1Postgraduate Program in Health Sciences, Federal University of Ceará, Sobral, Ceará, Brazil
- 2Microbiology Laboratory (LABMIC), Vale do Acaraú State University, Sobral, Ceará, Brazil
- 3Institute of Health Sciences, University for International Integration of Afro-Brazilian Lusophony, Redenção, Ceará, Brazil
- 4Faculty of Medicine, Federal University of Ceará, Sobral, Ceará, Brazil
Some Candida species of clinical interest have undergone recent nomenclature changes. These yeasts have a high capacity to adhere to and infect host tissues, driven by their virulence factors, as well as by the incidence of antifungal resistance. This review aimed to analyze the taxonomic changes of the main species of clinical interest within the Candida genus, considering the clinical implications of their virulence factors and the main mechanisms of antifungal resistance. The research results allowed us to understand that the updated nomenclature of Candida species is essential to maintain the criteria that define a genus, organizing the species according to their phylogenetic and evolutionary characteristics. Understanding the virulence factors and resistance mechanisms of the different species of clinical interest helps us understand how infections are initiated and established, as well as how these same species behave to neutralize the action of antifungals. Therefore, integrating knowledge of taxonomy, virulence, and resistance profiles is crucial for effective strategies to control and treat fungal infections.
Introduction
According to taxonomy, fungi are classified based on their phylogenetic characteristics, grouping organisms that share similar evolutionary traits. However, due to the complexity of fungi, taxonomic classification is subject to modifications over time to meet the criteria that define a genus. Some of the main Candida species have undergone changes in nomenclature, being renamed, subdivided within species, and reallocated into new clades (Kidd et al, 2023; Takashima and Sugita, 2022).
Yeasts of the genus Candida are unicellular microorganisms with spherical or oval shapes that live in the environment or are commonly part of the human microbiota, where they can be opportunistic pathogens. Some species can alter their morphology to a filamentous form, which is essential for adhesion and invasion of host cells (Lim et al., 2021; Pappas et al., 2018). This ability to perform morphological adaptations is one of the virulence factors presented by the genus, which favors the survival of the species in specific environments while facilitating superficial and invasive infections (Pappas et al., 2018).
Candida spp. are gaining more attention due to their ability to infect hosts and the high incidence of hospital-acquired invasive infections. They are recognized as a major cause of morbidity and mortality, stemming from their virulence factors that contribute to decreasing or nullifying the effect of antifungals (Pappas et al., 2016, Pappas et al, 2018). According to Baptista et al. (2020), approximately 80% of fungal infections reported in tertiary hospitals are attributed to yeast infections of the Candida genus.
Virulence factors not only increase the pathogenicity of Candida spp. but may also contribute to the antifungal resistance mechanisms developed by yeasts, allowing them to evade drug action. Antifungal resistance can be intrinsic or acquired, with reports of Candida spp. resistance to standard antifungals recurring (Czajka et al., 2023; Pappas et al., 2018; Thanyasrisung et al., 2023). Among the main antifungal resistance mechanisms presented by the Candida genus are genetic and enzymatic modifications, activation of efflux pumps, and those presented by biofilms (Miron-Ocampo et al., 2023; Nett and Andes, 2020). In view of the above, this review work aimed to analyze the taxonomic changes of the main species of clinical interest of the Candida genus, considering the clinical implications of their virulence factors and the main mechanisms of resistance to antifungals.
Changes in Candida spp. nomenclature
According to Kidd et al. (2023), over the past decade, fungal nomenclature has undergone significant transformations. This is due to advances in molecular technologies in taxonomy, diagnostics, and epidemiology, all aimed at meeting the criteria for defining a genus, such as monophyly, the range of species within a genus, and shared evolutionary and phylogenetic characteristics. Effective January 1, 2013, the practice of using different names for the teleomorph (sexual) and anamorph (asexual) states of fungi was prohibited. Therefore, mycologists must choose a single name from among the many that often already exist for the same species (Borman and Johnson, 2021).
The group of fungi that has undergone the most recent reclassifications and is causing the greatest concern among physicians and medical laboratories are the species of the genus Candida (Kidd et al., 2023). The genus Candida belongs to the phylum Ascomycota, class Saccharomycetes, and family Debaryomycetaceae. Multigene phylogenetic analyses suggest that the species of this genus can be grouped into more than 10 distinct clades, with occasional name changes and intraspecies subdivisions (Takashima and Sugita, 2022).
Among the species of clinical interest that have undergone reclassification are Candida glabrata, Candida krusei, Candida guilliermondii, and Candida lusitaniae, which are now named Nakaseomyces glabrata (Nakaseomyces), Pichia kudriavzevii (Pichiaceae), Meyerozyma guilliermondii (Debaryomycetaceae), and Clavispora lusitaniae (Metschnikowiaceae), respectively (Kidd et al., 2023; Takashima and Sugita, 2022). Candida parapsilosis has also undergone recent changes, remaining in the same clade, Lodderomyces, and has been subdivided into three: C. parapsilosis, C. orthopsilosis, and C. metapsilosis, also known as the Candida parapsilosis complex. The three species were organized as a single species for a long time (Takashima and Sugita, 2022; Govrins and Lass-Flörl, 2024).
The species C. albicans, C. parapsilosis, and C. tropicalis, which belong to the Lodderomyces clade, one of the largest clades with proven monophyly, retained the name Candida (Kidd et al., 2023; Stavrou et al., 2019; Takashima and Sugita, 2022). Candida auris, a multiresistant species, despite being part of the Metschnikovia clade, retained the same name (Kidd et al., 2023). New changes were made, and C. auris is now part of Candidozyma with the new nomenclature of Candidozyma auris (Liu et al., 2024).
Main virulence factors
Adhesion
Adhesion to host cells represents a critical step in the establishment of Candida spp. infections and is considered one of the first and most important virulence factors of these opportunistic yeasts. This process is mediated by specialized proteins called adhesins, which are located on the fungal cell surface and facilitate attachment to biotic and abiotic substrates (Nobile and Johnson, 2015; Alim et al, 2018; Wall et al., 2019). An important family of adhesins are the Als (Agglutinin-like sequence) proteins, particularly Als1, Als3, and Als5, which have high binding affinity for extracellular matrix components such as fibronectin, laminin, and collagen, favoring adhesion to epithelial and endothelial cells. Als expression is regulated by environmental factors and the morphological state of the cell, being intensified during the transition to the filamentous form (Lombardi et al., 2019; Oh et al., 2021; Pokhrel et al., 2022; Bing et al., 2023).
C. albicans also contains adhesins of the Hwp (Hyphal wall protein) family, which are associated with the formation of true hyphae. The Hwp1 protein binds to host cells, enabling the formation of covalent bonds between the fungus and epithelial surface proteins. This interaction is highly stable and confers adhesion that is resistant to fluid mechanics and the local immune response. It is primarily expressed under conditions that favor filamentous growth, such as the presence of serum and neutral pH, commonly found in host tissues during the infection phase (Nobile and Johnson, 2015; Pokhrel et al., 2022; Wooten et al., 2021).
N. glabrata, which does not form a filamentous structure, presents a distinct pathogenic profile. The adhesion process is mediated by a different family of adhesins, the EPA (Epithelial adhesins) (Valotteau et al., 2019). EPA1, EPA6, and EPA7 are primarily responsible for adhesion to human epithelial cells and vascular endothelium. EPA1-mediated adhesion occurs through the recognition of specific glycans on the surface of host cells, functioning as a highly specific ligand (López-Fuentes et al., 2018; Yu et al, 2018; Hassan et al, 2021).
Hydrolytic enzymes
The enzymes most frequently associated with the pathogenicity of Candida spp. are proteinases (SAPs), which act on albumin, the extracellular matrix, and host immunoglobulins. These enzymes are important in the process of adhesion to substrates, helping Candida species initiate the infectious process in host cells. They also have the unique characteristic of favoring the formation of pseudohyphae and hyphae, which are essential structures for tissue invasion (Czechowicz et al., 2022; Silva-Rocha et al., 2015).
Phospholipases, which break the ester bonds of phospholipids, facilitating yeast invasion. These enzymes are found on the surface of yeast and in germ tubes, playing a crucial role in the establishment of infection by degrading the phospholipid membrane of host cells. This degradation results in altered cellular characteristics, promoting greater adhesion of yeast to epithelial cells and medical devices, such as catheters and prostheses (Lim et al., 2021; Mroczyńska and Brillowska-Dąbrowska, 2021; Puello et al, 2023).
Lipase, which catalyzes the hydrolysis of triacylglycerols, and hemolysins are used by Candida species to degrade hemoglobin, promoting erythrocyte lysis, releasing iron, an essential nutrient for the growth and maintenance of fungal cells, and contributing to the survival of the pathogen in nutrient-limited environments (Lim et al., 2021; Mroczyńska and Brillowska-Dąbrowska, 2021; Nouraei et al., 2020).
Polymorphism
Morphological change is a key process in the transition of most Candida spp. from commensal to pathogenic, where the filamentous form is essential for invasion into host cells and medical devices. Among the species that can change their morphology from yeast to pseudohyphae and true hyphae are C. albicans and C. tropicalis, but to a lesser extent, thus being polymorphic species (Czechowicz et al., 2022; Talapko et al., 2021; Wu et al., 2016). C. albicans has the ability to form structures called germ tubes, which are young true hyphae that form when in contact with host blood cells, providing greater adhesion to substrates (Jung et al., 2020; Trovato et al., 2020). The only other species known to also have the ability to form a germ tube is C. dubliniensis (Navarathna et al., 2016; Sampath et al., 2017).
P. kudriavzevii, C. parapsilosis, and C. auris can produce pseudohyphae and are considered dimorphic species (Czechowicz et al., 2022; Du et al., 2020; Pitarch et al., 2018). N. glabrata develops only in its yeast form (blastoconidia), which is also its pathogenic morphology (Czechowicz et al., 2022; Pitarch et al., 2018). The absence of morphological change directly influences its clinical behavior and survival strategies in the host. The absence of filamentous forms limits its direct invasive capacity in tissues compared to other Candida species. However, N. glabrata compensates for this limitation with increased adhesion capacity to surfaces and formation of more resistant biofilms, factors that make eradication of the infection difficult (López-Fuentes et al., 2018; Olson et al, 2018; Yu et al, 2018; Frías-De-León et al., 2021).
Biofilm
Biofilms are highly organized biological communities where Candida spp. cells cluster together to form coordinated and functional structures. The cells can be mixed, composed of yeast, hyphae, and pseudohyphae, or solely yeast-like cells, such as the N. glabrata biofilm. They are immersed in a self-secreted extracellular matrix composed of proteins, carbohydrates, lipids, and DNA, establishing a complex three-dimensional structure that favors the entry of nutrients, the removal of waste, and the formation of microniches within the biofilm (Alim et al, 2018; Ghannoum et al., 2015; Silva et al., 2017; Wall et al., 2019).
These structures are regulated by a communication system called quorum sensing, where the cells of the forming biofilm communicate through lipid signals that control characteristics such as survival, pathogenicity factors, virulence, and behaviors in response to environmental conditions (Alim et al, 2018; Atriwal et al., 2021; Wall et al., 2019). Their formation is regulated by molecular processes in four distinct phases. Initially, yeast cells adhere to a surface, forming a base for the biofilm; over time, the cells proliferate and may develop filamentous structures, contributing to biofilm stability. During the maturation phase, the biofilm thickens due to the growth of the extracellular matrix, and its organization becomes three-dimensional. Eventually, dispersion occurs, in which cells detach from the biofilm and spread to other locations (Alim et al, 2018; Wall et al., 2019; Atriwal et al., 2021).
Candida species have a remarkable ability to form biofilms and are frequently found on hospital devices, dentures, prostheses, and especially catheters. On catheters, biofilms can develop intra and extraluminal adhesions (Alim et al, 2018; Atriwal et al., 2021; Silva et al., 2017; Wall et al., 2019). Biofilm formation on medical devices poses a significant clinical challenge, especially in hospital settings, conferring resistance to antifungals and hindering the immune system’s action, making infections persistent and difficult to treat (Thomaz et al., 2018; Jung et al., 2020; Melo et al., 2023).
Biofilm formation is one of the main reasons for antifungal treatment failure, as biofilm cells are protected from environmental stress and host defenses (Alim et al, 2018; Wall et al., 2019). Biofilms are difficult to treat due to their physical and genetic properties, presenting three main resistance mechanisms: the extracellular matrix that protects the cells, hindering the action of host defense cells and antifungal therapy; persister cells that acquire tolerance due to prolonged exposure to antifungals; and the activation of efflux pumps that occur during the primary stage of biofilm formation, adhesion (Nobile and Johnson, 2015; Silva et al., 2017; Atriwal et al., 2021; Kaur and Nobile, 2023).
Main mechanisms of planktonic cell resistance
The three main classes of antifungals are azoles, polyenes, and echinocandins, which have distinct targets of action. Azoles inhibit the fungal enzyme lanosterol 14-α-demethylase, encoded by the cytochrome P450 gene ERG11, which is the enzyme involved in ergosterol synthesis (Chang et al., 2017; Salazar et al., 2020). Among polyenes, the most commonly used drug is Amphotericin B; its mechanism of action is fungal cell death through the formation of pores in ergosterol-containing membranes (Chang et al., 2017; Salazar et al., 2020). And echinocandins act by inhibiting β-1,3-glucan synthase, an enzyme complex that acts in the synthesis of the fungal cell wall (Chang et al., 2017).
The resistance mechanisms developed by Candida species to antifungal classes may occur due to mutations in the ERG genes, reducing the effectiveness of azoles, or by amino acid substitutions near the 14-α-demethylase binding site and by activation of efflux pumps (Campoy and Adrio, 2017; Houšť et al, 2020; Salazar et al., 2020). Resistance to polyenes is considered very rare (Chang et al., 2017; Salazar et al., 2020), but the mechanisms involved are alterations that result from mutations in the ERG3 genes (Chang et al., 2017; Houšť et al, 2020; Salazar et al., 2020). The mechanisms of resistance to echinocandins are mutations in the FKS1 and FKS2 genes that result in amino acid substitutions in Hs1 and Hs2, which are called “hotspots”, which are regions of the FKS genes that act in the synthesis of the fungal cell wall (Chang et al., 2017; Daneshnia et al., 2023).
Discussion
According to Gabaldón et al (2016), Candida species are distributed throughout the Saccharomycotina phylogeny, present in most clades, and generally mixed with species from other genera, highlighting polyphyly, which differs from the criteria for genus definition. To adhere to taxonomic principles, new redefinitions are necessary so that species are organized within clades that suit their evolutionary and phylogenetic characteristics.
Adhesion mechanisms have important clinical implications that facilitate infection persistence. Their action in conjunction with hydrolytic enzymes contributes to evading the host’s immune response by modifying the local microenvironment (Talapko et al., 2021; Branco et al, 2023). Morphological transition is a key factor in the pathogenicity of most Candida species of clinical interest, associated with greater antifungal resistance, especially in biofilm infections. Therefore, they represent potential targets for new therapeutic strategies aimed at returning to the commensal stage and preventing biofilm formation.
Biofilm characteristics can vary according to the Candida species, presenting different responses to available therapies. In the study by Alves et al. (2023), the biofilm formed by isolates obtained from children had higher biomass and a matrix composition richer in polysaccharides than that isolated from adults. P. kudriavzevii was the most frequently isolated species in the children’s oral microbiota, and strains of this species also had higher biofilm biomass. The most frequently isolated species in adults was C. albicans, but it had a lower biofilm-forming capacity. The susceptibility of Candida spp. to antimicrobials in the biofilm of strains from the children’s group was directly associated with the amount of protein/polysaccharides, whereas no such relationship was observed in biofilms of strains from the adult group.
Fungal infections caused by planktonic cells intensify with biofilm formation, especially on medical devices, requiring differentiated therapeutic approaches. The activation and upregulation of efflux pumps in planktonic cells is triggered by the presence of antifungal drugs. In biofilm cells, this upregulation occurs naturally from the first hours of adhesion and persists throughout biofilm development, regardless of the presence of antifungal drugs (Nobile and Johnson, 2015; Kaur and Nobile, 2023). The distinct ways in which cells activate this mechanism help us understand the molecular processes involved in Candida spp. resistance due to efflux overexpression, demonstrating the essential need to develop clinical strategies that can overcome this barrier, such as the use of specific efflux inhibitors in combination with traditional antifungals.
Advances in molecular phylogeny and fungal taxonomy have reshaped our understanding of Candida species, leading to more than just name changes but also promoting the organization of species according to their shared phylogenetic and evolutionary characteristics. These changes reflect taxonomic advances, which, while not directly reflected in the virulence profiles of Candida spp., are important for understanding the pathogenic profiles and antifungal sensitivity/resistance across the various clades that comprise the Candida genus. The sophisticated virulence factors that favor immune evasion and prolong infections caused by Candida spp. highlight the importance of continuous updating in the medical and microbiological fields, revealing how evolutionary knowledge directly impacts the control of fungal infections, improving diagnosis, and tailoring therapies to the profiles of the causative species, aiming to reduce morbidity and mortality associated with fungal infections caused by these species.
Author contributions
MF: Writing – original draft, Investigation, Writing – review & editing, Methodology, Data curation. FA: Supervision, Validation, Writing – review & editing, Visualization. MC: Writing – review & editing, Resources. EB: Writing – review & editing, Visualization. CC: Visualization, Writing – review & editing. RF: Visualization, Resources, Validation, Funding acquisition, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. The authors are grateful for federal and state resources agencies for financial support. M.A.A.F. is the recipient of a master’s scholarship from the Coordination of Improvement of Higher Education Personnel (CAPES), Ministry of Education and Culture (MEC), Federal Government of Brazil. R.O.S.F. and M.G.S.C. is thankful to the State Funding Agency (FUNCAP), grant number FPD-0213-00362.01.00/23.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Alim D., Sircaik S., and Panwar S. L. (2018). The significance of lipids to biofilm formation in Candida albicans: An emerging perspective. J. Fungi 4, 140. doi: 10.3390/jof4040140
Alves A. M. C. V., Lopes B. O., Leite A. C. R. D. M., Cruz G. S., Brito É.H.S.D., Lima L. F. D., et al. (2023). Characterization of oral Candida spp. Biofilms in children and adults carriers from eastern europe and south america. . Antibiotics 12, 797. doi: 10.3390/antibiotics12050797
Atriwal T., Azeem K., Husain F. M., Hussain A., Khan M. N., Alajmi M. F., et al. (2021). Mechanistic understanding of Candida albicans biofilm formation and approaches for its inhibition. Front. Microbiol. 12. doi: 10.3389/fmicb.2021.638609
Baptista K. C. C., Nascimento K. F. do, Souza S. J. P. de, Burci L. M., Silva F. B., et al. (2020). Infecções hospitalares por Candida sp. em pacientes internados em UTI. Rev. Gestão Saúde 22, 66–81. doi: 10.17648/1984-8153-rgs-v2n22-6
Bing J., Guan Z., Zheng T., Zhang Z., Fan S., Ennis C. L., et al. (2023). Clinical isolates of Candida auris with enhanced adherence and biofilm formation due to genomic amplification of ALS4. PloS Pathog. 19, e1011239. doi: 10.1371/journal.ppat.1011239
Borman A. M. and Johnson E. M. (2021). Name changes for fungi of medical importance, 2018 to 2019. J. Clin. Microbiol. 59, 10.1128/jcm.01811-20. doi: 10.1128/jcm.01811-20
Branco J., Miranda I. M., and Rodrigues A. G. (2023). Candida parapsilosis virulence and antifungal resistance mechanisms: a comprehensive review of key determinants. J. Fungi 9, 80. doi: 10.3390/jof9010080
Campoy S. and Adrio J. L. (2017). Antifungals. Biochem. Pharmacol. 133, 86–96. doi: 10.1016/j.bcp.2016.11.019
Chang Y. L., Yu S. J., Heitman J., Wellington M., Chen Y. L., et al. (2017). New facets of antifungal therapy. Virulence 8, 222–236. doi: 10.1080/21505594.2016.1257457
Czajka K. M., Venkataraman K., Brabant-Kirwan D., Santi S. A., Verschoor C., Appanna V. D., et al. (2023). Molecular mechanisms associated with antifungal resistance in pathogenic Candida species. Cells 12, 2655. doi: 10.3390/cells12222655
Czechowicz P., Nowicka J., and Gościniak G. (2022). Virulence factors of Candida spp. and host immune response important in the pathogenesis of vulvovaginal candidiasis. Int. J. Mol. Sci. 23, 5895. doi: 10.3390/ijms23115895
Daneshnia F., Almeida Júnior J. N. de, Arastehfar A., Lombardi L., Shor E., Moreno L., et al. (2023). Candida parapsilosis isolates carrying mutations outside FKS1 hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance. Int. J. Antimicrobial Agents 62, 106831. doi: 10.1080/22221751.2022.2117093
Du H., Bing J., Hu T., Ennis C. L., Nobile C. J., and Huang G. (2020). Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PloS Pathog. 16, 1–18. doi: 10.1371/journal.ppat.1008921
Frías-De-León M. G., Hernández-Castro R., Conde-Cuevas E., García-Coronel I. H., Vázquez-Aceituno V. A., Soriano-Ursúa M. A., et al. (2021). Candida glabrata antifungal resistance and virulence factors, a perfect pathogenic combination. Pharmaceutics 13, 1529. doi: 10.3390/pharmaceutics13101529
Gabaldón T., Naranjo-Ortíz M. A., and Marcet-Houben M. (2016). Evolutionary genomics of yeast pathogens in the Saccharomycotina. FEMS Yeast Res. 16, :fow064. doi: 10.1093/femsyr/fow064
Ghannoum M., Roilides E., Katragkou A., Petraitis V., Walsh T. J., et al. (2015). The role of echinocandins in Candida biofilm–related vascular catheter infections: in vitro and in vivo model systems. Clin. Infect. Dis. 61, 618–621. doi: 10.1093/cid/civ815
Govrins M. and Lass-Flörl C. (2024). Candida parapsilosis complex in the clinical setting. Nat. Rev. Microbiol. 22, 46–59. doi: 10.1038/s41579-023-00961-8
Hassan Y., Chew S. Y., and Than L. T. L. (2021). Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival. J. Fungi 7, 667. doi: 10.3390/jof7080667
Houšť J., Spížek J., and Havlíček V. (2020). Antifungal drugs. Metabolites 10, 106. doi: 10.3390/metabo10030106
Jung P., Mischo C. E., Gunaratnam G., Spengler C., Becker S. L., Hube B., et al. (2020). Candida albicans adhesion to central venous catheters: Impact of blood plasma-driven germ tube formation and pathogen-derived adhesins. Virulence 11, 1453–1465. doi: 10.1080/21505594.2020.1836902
Kaur J. and Nobile C. J. (2023). Antifungal drug-resistance mechanisms in Candida biofilms. Curr. Opin. Microbiol. 71, e102237. doi: 10.1080/21505594.2020.1836902
Kidd S. E., Abdolrasouli A., and Hagen F. (2023). Fungal nomenclature: managing change is the name of the game. Open Forum Infectious Dis. 10, ofac559. doi: 10.1093/ofid/ofac559
Lim S. J., Ali M. S. M., Sabri S., Noor N. D. M., Salleh A. B., Oslan S. N., et al. (2021). Opportunistic yeast pathogen Candida spp.: Secreted and membrane-bound virulence factors. Med. Mycology 59, 1127–1144. doi: 10.1093/mmy/myab053
Liu F., Hu Z. D., Zhao X. M., Zhao W. N., Feng Z. X., Yurkov A., et al. (2024). Phylogenomic analysis of the Candida auris-Candida haemuli clade and related taxa in the Metschnikowiaceae, and proposal of thirteen new genera, fifty-five new combinations and nine new species. Persoonia-Molecular Phylogeny Evol. Fungi 52, 22–43. doi: 10.3767/persoonia.2024.52.02
Lombardi L., Zoppo M., Rizzato C., Bottai D., Hernandez A. G., Hoyer L. L., et al. (2019). Characterization of the Candida orthopsilosis agglutinin-like sequence (ALS) genes. PloS One 14, e0215912. doi: 10.1371/journal.pone.0215912
López-Fuentes E., Gutiérrez-Escobedo G., Timmermans B., Van Dijck P., De Las Peñas A., Castaño I., et al. (2018). Candida glabrata’s genome plasticity confers a unique pattern of expressed cell wall proteins. J. Fungi 4, 67. doi: 10.3390/jof4020067
Melo C. C. D., Sousa B. R. D., Costa G. L. D., Oliveira M. M. E., Lima-Neto R. G. D., et al. (2023). Colonized patients by Candida auris: Third and largest outbreak in Brazil and impact of biofilm formation. Front. Cell. Infection Microbiol. 13. doi: 10.3389/fcimb.2023.1033707
Miron-Ocampo A., Beattie S. R., Guin S., Conway T., Meyers M. J., Moye-Rowley W. S., et al. (2023). CWHM-974 is a fluphenazine derivative with improved antifungal activity against Candida albicans due to reduced susceptibility to multidrug transporter-mediated resistance mechanisms. Antimicrobial Agents Chemotherapy 67, e00567–e00523. doi: 10.1128/aac.00567-23
Mroczyńska M. and Brillowska-Dąbrowska A. (2021). Virulence of clinical Candida isolates. Pathogens 10, 466. doi: 10.3390/pathogens10040466
Navarathna D., Pathirana R. U., Lionakis M. S., Nickerson K. W., Roberts D. D., et al. (2016). Candida albicans ISW2 regulates chlamydospore suspensor cell formation and virulence in vivo in a mouse model of disseminated candidiasis. PloS One 11, e0164449. doi: 10.1371/journal.pone.0164449
Nett J. E. and Andes D. R. (2020). Contributions of the biofilm matrix to Candida pathogenesis. J. Fungi 6, 21. doi: 10.3390/jof6010021
Nobile C. J. and Johnson A. D. (2015). Candida albicans biofilms and human disease. Annu. Rev. Microbiol. 69, 71–92. doi: 10.1146/annurev-micro-091014-104330
Nouraei H., Pakshir K., ZareShahrabadi Z., Zomorodian K., et al. (2020). High detection of virulence factors by Candida species isolated from bloodstream of patients with candidemia. Microbial Pathogenesis 149, 104574. doi: 10.1016/j.micpath.2020.104574
Oh S. H., Isenhower A., Rodriguez-Bobadilla R., Smith B., Jones J., Hubka V., et al. (2021). Pursuing advances in DNA sequencing technology to solve a complex genomic jigsaw puzzle: the agglutinin-like sequence (ALS) genes of Candida tropicalis. Front. Microbiol. 11. doi: 10.3389/fmicb.2020.594531
Olson M. L., Jayaraman A., and Kao K. C. (2018). Relative abundances of Candida albicans and Candida glabrata in vitro coculture biofilms impact biofilm structure and formation. Appl. Environ. Microbiol. 84, e02769–e02717. doi: 10.1128/AEM.02769-17
Pappas P. G., Kauffman C. A., Andes D. R., Clancy C. J., Marr K. A., Ostrosky-Zeichner L., et al. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 62, 1–50. doi: 10.1093/cid/civ933
Pappas P. G., Lionakis M. S., Arendrup M. C., Ostrosky-Zeichner L., Kullberg B. J., et al. (2018). Invasive candidiasis. Nat. Rev. Dis. Primers 4, 1–20. doi: 10.1038/nrdp.2018.26
Pitarch A., Nombela C., and Gil C. (2018). Diagnosis of invasive candidiasis: from gold standard methods to promising leading-edge technologies. Curr. Topics Medicinal Chem. 18, 1375–1392. doi: 10.2174/1568026618666181025093146
Pokhrel S., Boonmee N., Tulyaprawat O., Pharkjaksu S., Thaipisutikul I., Chairatana P., et al. (2022). Assessment of biofilm formation by Candida albicans strains isolated from hemocultures and their role in pathogenesis in the zebrafish model. J. Fungi 8, 1014. doi: 10.3390/jof8101014
Puello M., Young G., and Suárez P. (2023). Actividad de fosfolipasas y proteasas en aislamientos de especies de Candida colonizadoras y causantes de vulvovaginitis en mujeres gestantes. Biomédica 43, 89–96. doi: 10.7705/biomedica.6759
Salazar S. B., Simões R. S., Pedro N. A., Pinheiro M. J., Carvalho M. F. N. N., and Mira N. P. (2020). An overview on conventional and non-conventional therapeutic approaches for the treatment of candidiasis and underlying resistance mechanisms in clinical strains. J. Fungi 6, 23. doi: 10.3390/jof6010023
Sampath A., Weerasekera M., Dilhari A., Gunasekara C., Bulugahapitiya U., Fernando N., et al. (2017). Comparison of duplex PCR and phenotypic analysis in differentiating Candida dubliniensis from Candida albicans from oral samples. AMB Express 7, 1–6. doi: 10.1186/s13568-017-0435-9
Silva-Rocha W. P., Lemos V. L. B., Ferreira M. R. A., Soares L. A. L., Svidzisnki T. I. E., Milan E. P., et al. (2015). Effect of the crude extract Eugenia uniflora in morphogensis and secretion of hydrolytic enzymes in Candida albicans from the oral cavit of kidney transplant recipients. Altern. Med. 15, 1–15. doi: 10.1186/s12906-015-0522-x
Silva S., Rodrigues C. F., Araújo D., Rodrigues M. E., Henriques M., et al. (2017). Candida species biofilms´ antifungal resistance. J. Fungi 3, 8. doi: 10.3390/jof3010008
Stavrou A. A., Lackner M., Lass-Flörl C., Boekhout T., et al. (2019). The changing spectrum of Saccharomycotina yeasts causing candidemia: phylogeny mirrors antifungal susceptibility patterns for azole drugs and amphothericin B. FEMS Yeast Res. 19, , foz037. doi: 10.1093/femsyr/foz037
Takashima M. and Sugita T. (2022). Taxonomy of pathogenic yeasts Candida, Cryptococcus, Malassezia, and Trichosporon current status, future perspectives, and proposal for transfer of six candida species to the genus nakaseomyces. Med. Mycology J. 63, 119–132. doi: 10.3314/mmj.22.004
Talapko J., Juzbašić M., Matijević T., Pustijanac E., Bekić S., Kotris I., et al. (2021). Candida albicans - the virulence factors and clinical manifestations of infection. J. Fungi 7, 79. doi: 10.3390/jof7020079
Thanyasrisung P., Satitviboon W., Howattanapanich S., Matangkasombut O., et al. (2023). Antifungal drug resistance in oral Candida isolates from HIV-infected and healthy individuals and efficacy of chitosan as an alternative antifungal agent. Arch. Oral. Biol. 147, 105628. doi: 10.1016/j.archoralbio.2023.105628
Thomaz D. Y., Almeida Jr J. N. D., Lima G. M. E., Nunes M. D. O., Camargo C. H., Grenfell R. D. C., et al. (2018). An azole-resistant Candida parapsilosis outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front. Microbiol. 9. doi: 10.3389/fmicb.2018.02997
Trovato L., Astuto M., Castiglione G., Scalia G., Oliveri S., et al. (2020). Diagnostic surveillance by Candida albicans germ tube antibody in intensive care unit patients. J. Microbiology Immunol. Infection 53, 778–784. doi: 10.1016/j.jmii.2019.02.001
Valotteau C., Prystopiuk V., Cormack B. P., Dufrêne Y. F., et al. (2019). Atomic force microscopy demonstrates that Candida glabrata uses three Epa proteins to mediate adhesion to abiotic surfaces. Msphere 4, 10.1128/msphere.00277-19. doi: 10.1128/mSphere.00277-19
Wall G., Montelongo-Jauregui D., Bonifacio B. V., Lopez-Ribot J. L., Uppuluri P., et al. (2019). Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Curr. Opin. Microbiol. 52, 1–6. doi: 10.1016/j.mib.2019.04.001
Wooten D. J., Zañudo J. G. T., Murrugarra D., Perry A. M., Dongari-Bagtzoglou A., Laubenbacher R., et al. (2021). Mathematical modeling of the Candida albicans yeast to hyphal transition reveals novel control strategies. PloS Comput. Biol. 17, e1008690. doi: 10.1371/journal.pcbi.1008690
Wu Y., Li Y. H., Yu S. B., Li W. G., Liu X. S., Zhao L., et al. (2016). A genomewide transcriptional analysis of yeast-hyphal transition in Candida tropicalis by RNASeq. PloS One 11, 1–16. doi: 10.1371/journal.pone.0166645
Keywords: Candida spp., taxonomic changes, virulence, resistance mechanisms, antifungals
Citation: Fernandes MAA, Aguiar FLLd, Coutinho MGS, Brito EHSd, Coelho CGV and Fontenelle ROdS (2025) Changes in nomenclature, virulence factors, and antifungal resistance of the genus Candida. Front. Fungal Biol. 6:1677892. doi: 10.3389/ffunb.2025.1677892
Received: 12 August 2025; Accepted: 18 September 2025;
Published: 15 October 2025.
Edited by:
Yuanwei Zhang, Nanjing Normal University, ChinaReviewed by:
Kássia Jéssica Galdino Silva, Université de Nantes, FranceCopyright © 2025 Fernandes, Aguiar, Coutinho, Brito, Coelho and Fontenelle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria Alyce Albuquerque Fernandes, YWx5Y2VhbGJ1cXVlcnF1ZTU1QGdtYWlsLmNvbQ==
†ORCID: Maria Alyce Albuquerque Fernandes, orcid.org/0009-0009-1975-4009
Francisca Lidiane Linhares de Aguiar, orcid.org/0000-0003-1733-2119
Maria Gleiciane Soares Coutinho, orcid.org/0000-0002-4268-9702
Erika Helena Salles de Brito, orcid.org/0000-0002-2807-4867
Camila Gomes Virginio Coelho, orcid.org/0009-0002-4390-4176
Raquel Oliveira dos Santos Fontenelle, orcid.org/0000-0002-8865-5954